KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Consolidated Net Income: 2009-2024

Historic Consolidated Net Income for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $561.8 million.

  • Jazz Pharmaceuticals' Consolidated Net Income rose 16.77% to $251.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $565.9 million, marking a year-over-year increase of 21.63%. This contributed to the annual value of $561.8 million for FY2024, which is 34.45% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Consolidated Net Income stood at $561.8 million for FY2024, which was up 34.45% from $417.8 million recorded in FY2023.
  • In the past 5 years, Jazz Pharmaceuticals' Consolidated Net Income registered a high of $561.8 million during FY2024, and its lowest value of -$329.0 million during FY2021.
  • Over the past 3 years, Jazz Pharmaceuticals' median Consolidated Net Income value was $417.8 million (recorded in 2023), while the average stood at $255.2 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first tumbled by 236.17% in 2021, then skyrocketed by 295.13% in 2023.
  • Jazz Pharmaceuticals' Consolidated Net Income (Yearly) stood at $241.6 million in 2020, then plummeted by 236.17% to -$329.0 million in 2021, then spiked by 34.90% to -$214.1 million in 2022, then spiked by 295.13% to $417.8 million in 2023, then surged by 34.45% to $561.8 million in 2024.